Risperidone Versus Olanzapine for Treatment of Schizophrenia
| Autor: | T. S. Stroup, Prakash Hosalli, Mahesh Jayaram |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Olanzapine
medicine.medical_specialty medicine.drug_class Atypical antipsychotic law.invention Benzodiazepines Randomized controlled trial Extrapyramidal symptoms law Internal medicine medicine Humans Psychiatry Adverse effect Risperidone Positive and Negative Syndrome Scale business.industry Special Features Psychiatry and Mental health Schizophrenia medicine.symptom business Weight gain Antipsychotic Agents medicine.drug |
| Zdroj: | Schizophrenia Bulletin. 33:1274-1276 |
| ISSN: | 1745-1701 0586-7614 |
| DOI: | 10.1093/schbul/sbm101 |
| Popis: | We found no difference for the outcome of unchanged or worse in the short term (n = 548, 2 randomized control trial (RCTs), RR = 1.00, 95% CI = 0.88 to 1.15). One study favored olanzapine for the outcome of relapse/rehospitalization by 12 months (n = 279, 1 RCT, RR = 2.16, 95% CI = 1.31 to 3.54, NNH = 7, 95% CI = 3 to 25). Most mental state data showed the 2 drugs to be as effective as each other (n = 552, 2 RCTs, RR ‘no |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|